Results 31 to 40 of about 2,731,118 (178)

In Vivo Emergence of Tigecycline Resistance in Multidrug-Resistant Klebsiella pneumoniae and Escherichia coli [PDF]

open access: yesAntimicrobial Agents and Chemotherapy, 2012
Although resistance to tigecycline has been reported in surveillance studies, a very few reports described the emergence of resistance in vivo.
Sganga, Gabriele   +22 more
core   +5 more sources

Occurrence and mechanisms of tigecycline resistance in carbapenem- and colistin-resistant Klebsiella pneumoniae in Thailand [PDF]

open access: yesScientific Reports
Tigecycline has been regarded as one of the most important last-resort antibiotics for the treatment of infections caused by extensively drug-resistant (XDR) bacteria, particularly carbapenem- and colistin-resistant Klebsiella pneumoniae (C-C-RKP ...
Nachat Chirabhundhu   +6 more
doaj   +2 more sources

The Mechanism of Tigecycline Resistance in Acinetobacter baumannii Revealed by Proteomic and Genomic Analysis. [PDF]

open access: yesInt J Mol Sci, 2023
The mechanism of tigecycline resistance in A. baumannii remains largely unclear. In this study, we selected a tigecycline-resistant and a tigecycline-susceptible strain from a tigecycline-susceptible and a resistant strain, respectively.
Liu C, Wang L, Wang P, Xiao D, Zou Q.
europepmc   +2 more sources

A review of tigecycline resistance in nontuberculous mycobacteria. [PDF]

open access: yesMol Biol Rep
Abstract The genus Mycobacterium comprises nontuberculous mycobacteria (NTM), which are opportunistic environmental pathogens primarily associated with chronic lung disease.
Moura CDS, da Silva WMV, Ramos JP.
europepmc   +2 more sources

A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae [PDF]

open access: yesFrontiers in Cellular and Infection Microbiology, 2022
The increasing incidence of tigecycline resistance undoubtedly constitutes a serious threat to global public health. The combination therapies had become the indispensable strategy against this threat. Herein, 11 clinical tigecycline-resistant Klebsiella pneumoniae which mainly has mutations ...
Lilan Sun   +7 more
openaire   +3 more sources

Tigecycline Heteroresistance and Resistance Mechanism in Clinical Isolates of Acinetobacter baumannii

open access: yesMicrobiology Spectrum, 2021
Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In this study, we investigated tigecycline heteroresistance in A.
Jeongwoo Jo, Kwan Soo Ko
doaj   +1 more source

Acquisition of Tigecycline Resistance by Carbapenem-Resistant Klebsiella pneumoniae Confers Collateral Hypersensitivity to Aminoglycosides

open access: yesFrontiers in Microbiology, 2021
Tigecycline is a last-resort antibiotic for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This study aimed to broaden our understanding of the acquisition of collateral hypersensitivity by CRKP, as an evolutionary trade-off of ...
Hua-le Chen   +9 more
doaj   +1 more source

High tigecycline resistance in multidrug-resistant Acinetobacter baumannii [PDF]

open access: yesJournal of Antimicrobial Chemotherapy, 2007
Multidrug-resistant (MDR) Acinetobacter baumannii is increasing in our hospital and worldwide, raising the necessity of finding effective therapies. We aimed to evaluate the in vitro activity of tigecycline against MDR A. baumannii clones isolated before tigecycline was used in our institution.Eighty-two unique patient clinical isolates of multidrug ...
Shiri, Navon-Venezia   +2 more
openaire   +2 more sources

Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf

open access: yesEmerging Microbes and Infections, 2021
Acinetobacter baumannii is an important pathogen in hospital acquired infections. Although tigecycline currently remains a potent antibiotic for treating infections caused by multidrug resistant A.
Xiaoting Hua   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy